Our investigation of immune checkpoints and TMB in high- and low-risk groups revealed that the expression levels of immune checkpoints, including VTCN1, CD200R1, TNFRSF14, NRP1, TNFRSF4, CD40, CD200, CD44, TNFRSF25, CD48, and CD40LG, decreased in the BRCA high-risk group. This evidence concerns the gene TNFRSF14 and invasive breast carcinoma.